United States: Split Federal Circuit Decision Revives Antitrust Counterclaims In Patent Litigation

The U.S. Court of Appeals for the Federal Circuit has remanded for further consideration antitrust claims accusing a patent holder of filing a sham infringement suit and a sham citizen petition with the Federal Drug Administration. The case is Tyco Healthcare Group LP v. Mutual Pharmaceutical Co. (Fed. Cir., Aug. 6, 2014). This split decision has significant implications both for patent holders planning to assert infringement claims and for infringement defendants considering antitrust counterclaims.


Sandoz Limited applied for several patents directed to formulations and features of, and methods of treatment with, temazepam, a drug used to treat insomnia. In 2001, Tyco Healthcare Group LP and Mallinckrodt, Inc. ("Tyco") acquired the patents from Sandoz, and currently markets temazepam under the brand name Restoril. The patents were listed in the FDA's Orange Book.

In 2006, Mutual Pharmaceutical Company, Inc. and United Research Laboratories, Inc. ("Mutual") filed an Abbreviated New Drug Application ("ANDA") with the FDA, seeking approval to manufacture and sell a generic version of temazepam. Mutual filed the certification under paragraph IV of U.S.C. § 355(j)(2)(A)(vii), asserting that its generic product would not infringe Tyco's patents.

Tyco then sued Mutual for patent infringement. Tyco subsequently filed a citizen petition with the FDA, proposing guidelines that would require generic temazepam manufacturers to demonstrate bioequivalence to Restoril. Mutual filed antitrust counterclaims, asserting: (1) Tyco's infringement claim constituted sham litigation, (2) Tyco's citizen petition was a sham, and (3) Tyco sought to enforce patents obtained by means of fraud on the Patent Office.

The district court found that Mutual did not infringe Tyco's patents and found the patents in question to be invalid. The FDA approved Mutual's ANDA without waiting to decide Tyco's citizen's petition and later formally denied Tyco's citizen's petition. Subsequently, the district court granted summary judgment to Tyco with respect to Mutual's antitrust counterclaims (D.N.J.,

Jan. 18, 2013).

Federal Circuit Opinion

The Federal Circuit affirmed the district court in part, vacated in part, and remanded for further consideration. The Federal Circuit affirmed with respect to Mutual's Walker Process fraud claim, agreeing with the district court that Mutual did not present any evidence that Tyco "knew that Sandoz had engaged in a deliberately planned and carefully executed scheme to defraud the Patent Office" at the time that Tyco filed its infringement action. The Federal Circuit also held that Tyco's defense of the validity of its patents, although ultimately unsuccessful, was not objectively baseless since Tyco presented evidence that the prior art taught away from the claimed invention.

However, the Federal Circuit vacated the district court's summary judgment that Tyco's infringement claims were not a sham. The court confirmed that determination of whether a claim is objectively baseless requires a factual inquiry and therefore remanded the case for further consideration. The court also concluded that the district court applied the wrong legal standard by failing to determine whether Tyco's citizen petition was a sham. On remand, the district court was instructed to determine whether the citizen petition caused any injury to Mutual in the form of delay in the approval of Mutual's ANDA.


This decision has significant implications for both patent owners and alleged infringers. First, the decision provides a reminder that Walker Process fraud claims require proof not only of fraud on the PTO, but also of exclusion, which only occurs with enforcement. Accordingly, the offense was not complete with Sandoz's alleged fraudulent actions before the PTO. Mutual also had to prove that Tyco knew of Sandoz's conduct at the time it enforced the patents. Since Mutual was unable to do so, the court rejected Mutual's claim of fraud on the PTO.

Second, the decision confirms that the presumption of validity for a patent holder creates a very high barrier to a party claiming sham litigation based on invalidity. However, this presumption can be overcome. The dissent's suggestion that a patent owner may, as a matter of law, rely on the presumption of validity to defeat any claim of sham litigation was not accepted by the majority.

Third, the decision confirms that a pharmaceutical patent owner may allege infringement "if the patent owner has evidence that the as-marketed commercial ANDA product will infringe, even though the hypothetical product specified in the ANDA could not infringe." (The court referred to various situations in which a generic manufacturer's ANDA application could describe a generic drug "with characteristics that take it outside the patent's claims," but the only product that realistically could be marketed is likely to infringe the patent.).

Fourth, the decision establishes that courts will engage in a factual analysis to determine whether a patent owner's infringement claim is a sham. The majority refused to accept the dissent's position that an ANDA certification is sufficient as a matter of law to make an infringement claim reasonable. It is noteworthy that Tyco's final remaining patent in the litigation was not a formulation patent; it is unclear whether the dissent's position might carry more weight in a case involving a formulation patent.

Finally, the decision confirms that the Federal Circuit will apply the sham litigation standard to FDA citizen petitions, citing favorably a Second Circuit decision reaching the same conclusion while also holding that administrative petitions are "less susceptible than lawsuits to the sham exception." The majority then held that disputed issues of fact precluded summary judgment on the objectively baseless prong of the sham standard. In particular, the majority focused on the FDA's response to the petition, which included approving Mutual's pending ANDA despite the pendency of the petition and the later denial of the petition "in terms indicating that, in the FDA's view, it was wholly without merit." According to the majority, the subjective prong of the sham standard could be satisfied from the fact that the citizen's petition was filed the day after the district court entered a determination of noninfringement.) On remand, however, the majority instructed the district court to consider whether Mutual could show antitrust injury in light of the fact that its ANDA had been approved despite the pendency of the petition. The dissent would have affirmed the district court's grant of summary judgment on the grounds that Tyco's petition was accurate.

The Federal Circuit's August 6, 2014 opinion.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.